Victor J. Dzau is the President of the National Academy of Medicine (NAM), formerly the Institute of Medicine (IOM). In addition, he serves as Chair of the Health and Medicine Division Committee of the National Academies of Sciences, Engineering, and Medicine, and Vice Chair of the National Research Council.
Dr. Dzau is Chancellor Emeritus and James B. Duke Professor of Medicine at Duke University and the past President and CEO of the Duke University Health System. Previously, Dr. Dzau was the Hersey Professor of Theory and Practice of Medicine and Chairman of Medicine at Harvard Medical School’s Brigham and Women’s Hospital, as well as Chairman of the Department of Medicine at Stanford University.
Dr. Dzau has made a significant impact on medicine through his seminal research in cardiovascular medicine and genetics and his leadership in health care innovation. His important work on the renin angiotensin system (RAS) paved the way for the contemporary understanding of RAS in cardiovascular disease and the development of RAS inhibitors as widely used, lifesaving drugs. In his role as a leader in health care, Dr. Dzau has led efforts in innovation to improve health, including the development of the Duke Translational Medicine Institute, the Duke Global Health Institute, the Duke-National University of Singapore Graduate Medical School, and the Duke Institute for Health Innovation.
As one of the world’s preeminent health leaders, Dr. Dzau advises governments, corporations, and universities worldwide. He has served as a member of the Advisory Committee to the Director of the National Institutes of Health (NIH) and as Chair of the NIH Cardiovascular Disease Advisory Committee. Currently he is a member of the Board of the Singapore Health System and Hamad Medical Corporation, Qatar. He was on the Board of Health Governors of the World Economic Forum and chaired its Global Agenda Council on Personalized and Precision Medicine.
Since arriving at the National Academies, Dr Dzau has emphasized Leadership, Innovation, and Impact. He has led important initiatives such as the Global Health Risk Framework for the Future, the Human Gene Editing Initiative, Vital Directions for Health and Healthcare, and Grand Challenges in Health and Medicine. His vision is to advance science and policy to improve health globally.
Among his many honors and recognitions are the Gustav Nylin Medal from the Swedish Royal College of Medicine, the Distinguished Scientist Award from the American Heart Association, Ellis Island Medal of Honor, and the Henry Freisen International Prize. In 2014, he received the Public Service Medal from the President of Singapore. He is a member of the National Academy of Medicine, the American Academy of Arts and Sciences and the European Academy of Sciences and Arts. He has received eight honorary doctorates.
Back to Board of Directors and Officers